ID   C-643
AC   CVCL_5969
SY   C 643; C643; c643
DR   BTO; BTO:0005149
DR   cancercelllines; CVCL_5969
DR   CCRID; 3101HUMSCSP545
DR   CLS; 300298
DR   Cosmic; 888095
DR   Cosmic; 888279
DR   Cosmic; 889491
DR   Cosmic; 913251
DR   Cosmic; 1068625
DR   Cosmic; 1084282
DR   Cosmic; 1152117
DR   Cosmic; 1155331
DR   Cosmic; 1239971
DR   Cosmic; 1280042
DR   Cosmic; 1507379
DR   Cosmic; 1533557
DR   Cosmic; 1536132
DR   Cosmic; 1889012
DR   Cosmic; 2036693
DR   Cosmic; 2054091
DR   Cosmic; 2186783
DR   Cosmic; 2319850
DR   Cosmic; 2786688
DR   Cosmic; 2791079
DR   IARC_TP53; 21626
DR   IBRC; C10312
DR   Wikidata; Q54799751
RX   PubMed=2848260;
RX   PubMed=14522906;
RX   PubMed=17465858;
RX   PubMed=17725429;
RX   PubMed=18713817;
RX   PubMed=19087340;
RX   PubMed=21868764;
RX   PubMed=23833040;
RX   PubMed=25365311;
RX   PubMed=26680454;
RX   PubMed=30737244;
RX   PubMed=31368081;
CC   Doubling time: 23 hours (PubMed=31368081).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe341Leu (c.1023T>G); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=14522906; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 28873; VTCN1; Simple; p.Tyr215Ter (c.645C>G); Zygosity=Unspecified (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): CLS=300298; PubMed=17465858; PubMed=18713817; PubMed=21868764; PubMed=25365311; PubMed=30737244; PubMed=31368081
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,10
ST   D16S539: 9,13
ST   D18S51: 14 (PubMed=31368081)
ST   D18S51: 14,17 (PubMed=17465858)
ST   D18S51: 14,18 (CLS=300298; PubMed=18713817; PubMed=30737244)
ST   D21S11: 28
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 9,12
ST   D8S1179: 11,13
ST   FGA: 18,21
ST   Penta D: 9
ST   Penta E: 5,15
ST   TH01: 9.3,10
ST   TPOX: 11,12
ST   vWA: 15,17
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
//
RX   PubMed=2848260; DOI=10.1073/pnas.85.23.9302;
RA   Heldin N.-E., Gustavsson B., Claesson-Welsh L., Hammacher A., Mark J.,
RA   Heldin C.-H., Westermark B.;
RT   "Aberrant expression of receptors for platelet-derived growth factor
RT   in an anaplastic thyroid carcinoma cell line.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:9302-9306(1988).
//
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//
RX   PubMed=17465858; DOI=10.1089/thy.2006.0246;
RA   Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E.,
RA   Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.;
RT   "Molecular cytogenetic profiles of novel and established human
RT   anaplastic thyroid carcinoma models.";
RL   Thyroid 17:289-301(2007).
//
RX   PubMed=17725429; DOI=10.1089/thy.2007.0097;
RA   Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V.,
RA   Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R.,
RA   Trovisco V., Cirnes L., Alves C., Velho S., Soares P.,
RA   Sobrinho-Simoes M.;
RT   "Molecular and genotypic characterization of human thyroid follicular
RT   cell carcinoma-derived cell lines.";
RL   Thyroid 17:707-715(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=19087340; DOI=10.1186/1471-2407-8-371;
RA   Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.;
RT   "Conventional and molecular cytogenetics of human non-medullary
RT   thyroid carcinoma: characterization of eight cell line models and
RT   review of the literature on clinical samples.";
RL   BMC Cancer 8:371.1-371.11(2008).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25365311; DOI=10.1210/jc.2014-2359;
RA   Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T.,
RA   Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S.,
RA   Liu L.-Z., Tan K.T., Chang W.J., Yang H., Ogawa S., Koeffler H.P.;
RT   "Establishment and characterization of novel human primary and
RT   metastatic anaplastic thyroid cancer cell lines and their genomic
RT   evolution over a year as a primagraft.";
RL   J. Clin. Endocrinol. Metab. 100:725-735(2015).
//
RX   PubMed=26680454; DOI=10.1186/s12885-015-1955-9;
RA   Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J.,
RA   Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.;
RT   "The genomic and transcriptomic landscape of anaplastic thyroid
RT   cancer: implications for therapy.";
RL   BMC Cancer 15:984.1-984.11(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=31368081; DOI=10.1007/s12020-019-02009-5;
RA   Pinto A.T., Pojo M., Simoes-Pereira J., Roque R., Saramago A.,
RA   Roque L., Martins C., Andre S., Cabecadas J., Leite V., Cavaco B.M.;
RT   "Establishment and characterization of a new patient-derived
RT   anaplastic thyroid cancer cell line (C3948), obtained through
RT   fine-needle aspiration cytology.";
RL   Endocrine 66:288-300(2019).
//